Unit 4 site located in Pashamylaram, near Hyderabad produces injectable and ophthalmic drugs accounting for 7-8 percent of US sales and has 47 abbreviated new drug application pending for approval.
At least eight of the group companies have come together to build the ecosystem. The first project is the new Tata Nexon EV.
As per the request for proposal for book running lead managers (BRLMs) floated by the SBI Card, the company intends to tap capital markets via IPO through 'offer for sale' by dilution of up to 14 per cent of the issued and paid up capital (up to 13.05 crore) equity shares and primary issuance of up to Rs 1,000 crore.
It is looking at raising debt of Rs 450 crore for the Eluru project and Rs 400 crore for the Bengaluru project, the official added.